Resumen
Background: Primary care providers (PCPs) have always played an important role in cancer diagnosis. There is increasing awareness of the importance of their role during treatment and survivorship. We examined changes in PCP utilization from pre-diagnosis to survival for women diagnosed with breast cancer, factors associated with being a high user of primary care, and variation across four Canadian provinces. Methods: The cohorts included women 18+ years of age diagnosed with stage I-III invasive breast cancer in years 2007-2012 in British Columbia (BC), Manitoba (MB), Ontario (ON), and Nova Scotia (NS) who had surgery plus adjuvant chemotherapy and were alive 30+ months after diagnosis (N = 19,589). We compared the rate of PCP visits in each province across phases of care (pre-diagnosis, diagnosis, treatment, and survival years 1 to 4). Results: PCP use was greatest during treatment and decreased with each successive survival year in all provinces. The unadjusted difference in PCP use between treatment and pre-diagnosis was most pronounced in BC where PCP use was six times higher during treatment than pre-diagnosis. Factors associated with being a high user of primary care during treatment included comorbidity and being a high user of care pre-diagnosis in all provinces. These factors were also associated with being a higher user of care during diagnosis and survival. Conclusions: Contrary to the traditional view that PCPs focus primarily on cancer prevention and early detection, we found that PCPs are involved in the care of women diagnosed with breast cancer across all phases of care.
Idioma original | English |
---|---|
Número de artículo | s12875-019-1052-2 |
Publicación | BMC Family Practice |
Volumen | 20 |
N.º | 1 |
DOI | |
Estado | Published - nov. 21 2019 |
Nota bibliográfica
Funding Information:The authors thank Dongdong Li for conducting statistical analyses in British Columbia. The authors would also like to thank ICES, a non-profit institution funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC) and Cancer Care Ontario (CCO) which provided data and information. The opinions, results, view, and conclusions reported in this paper are those of the authors and do not necessarily reflect those of ICES, the Ontario MOHLTC, or CCO; no endorsement, ICES, the Ontario MOHLTC, or CCO is intended or should be inferred. We gratefully acknowledge the data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI. We gratefully acknowledge CancerCare Manitoba for their on-going support and Manitoba Health for the provision of data. The results and conclusions presented are those of the authors and no official endorsement by Manitoba Health is intended or should be inferred. We also thank Health Data Nova Scotia and the Nova Scotia Department of Health and Wellness for the provision of data. The observations and opinions expressed are those of the authors and do not represent those of either Health Data Nova Scotia or the Department of Health and Wellness. Lastly, we gratefully acknowledge the data provided by Population Data BC and the BC Cancer Agency. All inferences, opinions, and conclusions drawn in this study are those of the authors, and do not reflect the opinions or policies of the BC Data Steward(s).
Funding Information:
Funding for this study was provided by the Canadian Institutes of Health Research (CIHR; grant 128272) and the Canadian Centre for Applied Research in Cancer Control, funded by Canadian Cancer Society (grant #2015–703549). The funding agencies had no role in the design of the study and collection, analysis, and interpretation of the data or in the writing of the manuscript.
Publisher Copyright:
© 2019 The Author(s).
ASJC Scopus Subject Areas
- Family Practice
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't